Apollo Ingredients Ltd
₹ 9.67
4.99%
12 Feb
- close price
About
Incorporated in 1980, Apollo Ingredients Ltd is
in the business of providing healthcare solutions[1]
Key Points
- Market Cap ₹ 10.1 Cr.
- Current Price ₹ 9.67
- High / Low ₹ 9.67 / 5.43
- Stock P/E 10.7
- Book Value ₹ 5.95
- Dividend Yield 0.00 %
- ROCE 10.6 %
- ROE 8.13 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -6.69% over past five years.
- Company has a low return on equity of 2.55% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.55 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 4.34 | 4.58 | 2.37 | 0.00 | 1.00 | 3.07 | 4.59 | |
| 5.48 | 0.51 | 0.17 | 0.17 | 0.17 | 0.17 | 4.26 | 4.45 | 2.41 | 0.10 | 0.92 | 2.95 | 3.65 | |
| Operating Profit | 0.07 | -0.11 | -0.17 | -0.17 | -0.17 | -0.17 | 0.08 | 0.13 | -0.04 | -0.10 | 0.08 | 0.12 | 0.94 |
| OPM % | 1.26% | -27.50% | 1.84% | 2.84% | -1.69% | 8.00% | 3.91% | 20.48% | |||||
| 0.24 | 0.19 | 0.12 | 0.12 | 0.11 | 0.10 | 0.11 | 0.14 | 0.12 | 0.03 | 0.00 | 0.01 | 0.00 | |
| Interest | 0.14 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.17 | -0.01 | -0.05 | -0.05 | -0.06 | -0.07 | 0.19 | 0.27 | 0.08 | -0.07 | 0.08 | 0.13 | 0.94 |
| Tax % | 29.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 15.79% | 22.22% | 25.00% | 0.00% | 25.00% | 23.08% | |
| 0.12 | -0.01 | -0.05 | -0.05 | -0.06 | -0.07 | 0.16 | 0.21 | 0.06 | -0.07 | 0.06 | 0.10 | 0.94 | |
| EPS in Rs | 0.06 | -0.07 | 0.06 | 0.10 | 0.90 | ||||||||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | -7% |
| 3 Years: | 9% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | -9% |
| 3 Years: | 19% |
| TTM: | 683% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 6% |
| 3 Years: | 3% |
| Last Year: | 8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 5.20 |
| Reserves | 1.00 | 1.00 | 0.95 | 0.69 | 0.63 | 0.56 | 0.72 | 0.93 | 0.99 | 0.92 | 0.98 | 1.08 | 0.99 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.24 | 0.20 | 0.01 | 0.01 | 0.01 | 0.01 | 0.10 | 0.01 | 0.02 | 0.04 | 0.54 | 0.40 | 0.30 | |
| Total Liabilities | 1.44 | 1.40 | 1.16 | 0.90 | 0.84 | 0.77 | 1.02 | 1.14 | 1.21 | 1.16 | 1.72 | 1.68 | 6.49 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.21 | 0.21 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 1.23 | 1.19 | 0.95 | 0.90 | 0.84 | 0.77 | 1.02 | 1.14 | 1.21 | 1.16 | 1.72 | 1.68 | 6.49 | |
| Total Assets | 1.44 | 1.40 | 1.16 | 0.90 | 0.84 | 0.77 | 1.02 | 1.14 | 1.21 | 1.16 | 1.72 | 1.68 | 6.49 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | -0.01 | 0.01 | 0.00 | 0.00 | -0.01 | 0.11 | -0.04 | 0.01 | 0.10 | 1.47 | -0.12 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | |
| Net Cash Flow | 0.00 | -0.01 | 0.01 | 0.00 | 0.00 | -0.01 | 0.11 | -0.04 | 0.01 | 0.11 | 1.47 | -0.12 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Working Capital Days | 63.79 | 894.25 | 66.44 | 82.88 | 166.33 | -164.25 | -32.10 | |||||
| ROCE % | 27.07% | 6.67% | -4.26% | -4.90% | -6.98% | -8.81% | 22.62% | 26.34% | 6.90% | -6.06% | 6.96% | 10.57% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15h - Monitoring agency reports Rs.3.00 crore (of Rs.5.00 crore rights) used for related-party lease; deviation 50-75%.
-
Outcome Of The Board Meeting For The Quarter Ended 31St December, 2025- Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015.
16h - Q3 FY26 unaudited results approved; LR unqualified; Rs3 crore rights-issue proceeds used for related-party lease; MD/CFO remuneration approved.
-
Board Meeting Outcome for Outcome Of The Board Meeting- Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015
16h - Approved Q2 results; Rs3.00 crore rights-issue proceeds used for related-party lease; MD/CFO remuneration approved.
-
Board Meeting Intimation for Intimation Of The Board Meeting Of The Company.
11 Feb - Board meeting 14 Feb 2026 to consider unaudited results for quarter ended 31-Dec-2025 and MD/CFO remuneration.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Filing Of Appeal Before Securities Appellate Tribunal (SAT)
27 Jan - Filed SAT appeal (No. 23 of 2026) against BSE fines and promoter demat freezes, lodged 27 Jan 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
AIL (formerly Indsoya Ltd) is an integrated healthcare solutions provider focusing on the manufacture, import, and export of Ayurvedic, Homeopathic, and Allopathic medicines. The company is also expanding into setting up and managing hospitals, diagnostic and wellness centres, and pathology labs, while offering value-added services such as clinical audits, hospital consultancy, and healthcare staffing solutions. It aims to leverage opportunities across traditional and modern medical systems both in India and international markets.